Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

摘要: Current chemotherapy treatment of metastatic non-small cell lung cancer has demonstrated some objective responses, but is still largely palliative. This report reviews the results a randomized trial in patients with advanced which compared supportive care (treatment palliative radiation, psychosocial support, analgesics, nutritional support) to plus combination cisplatin and vinblastine. Although receiving had slightly longer median survival (20.43 weeks versus 13.57 weeks), it was not statistically significant (P = 0.09). In addition, experienced serious toxicity, showed no benefit terms quality life as measured by Karnofsky performance status score. The authors conclude that contemporary provides only modest should be considered standard therapy. Future investigations unresectable continue utilize control arms provide high-quality care.